Tag Archives: Survodutide

Boehringer Ingelheim’s Survodutide Shows Promising Results as Potential Best-in-Class Treatment for MASH in Phase II Trial

(IN BRIEF) Boehringer Ingelheim has reported compelling results from its Phase II trial of Survodutide, a novel glucagon/GLP-1 receptor dual agonist, indicating its potential to become a leading treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH). In the trial, up to 83.0% … Read the full press release

Boehringer Ingelheim Advances Dual Agonist Survodutide to Phase III Trials, Demonstrating Significant Weight Loss in Phase II Study

(IN BRIEF) Pharmaceutical company Boehringer Ingelheim has declared its intention to move forward with survodutide, a dual agonist targeting the glucagon/GLP-1 receptors, into three Phase III clinical trials for individuals suffering from overweight or obesity. This decision stems from promising … Read the full press release